Comprehensive Pharmacogenomic-Informed Population Pharmacokinetic-Pharmacodynamic Model for Clozapine: A Multi-Receptor PBPK Framework with Clinical Decision Support Implementation

This file contains an advanced physiologically-based pharmacokinetic (PBPK) and pharmacodynamic (PD) modeling framework for clozapine, integrating complex genetic polymorphisms, multi-receptor binding kinetics, and clinical therapeutic drug monitoring (TDM) recommendations using the R-based mrgsolve package. Model Scope and Features: Pharmacokinetic Component: • Three-compartment central-peripheral distribution model with dedicated brain-blood barrier (BBB) transport • Regional brain compartmentalization: cortical and striatal regions with physiologically realistic penetration ratios (10-30%) • Comprehensive genetic polymorphism modeling for 10+ drug-metabolizing enzymes and transporters: • CYP450 isoforms (CYP1A2, CYP2D6, CYP3A4) with phenotype-specific activity factors • Flavin-monooxygenase (FMO3) and glutathione-S-transferase enzymes (GSTT1, GSTM1, GST) • Transporter proteins (ABCB1/P-glycoprotein, SLCO1B1/OATP1B1, ABCC2/MRP2) • CYP3A4*22 reduced-activity allele implementation • Metabolite formation tracking: norclozapine, clozapine N-oxide, and reactive metabolites • Glutathione depletion kinetics with hepatic zonation effects • Smoking- and ethnicity-dependent clearance modifications • Drug-drug interactions with fluvoxamine (strong CYP1A2 inhibitor) Pharmacodynamic Component: • Multi-receptor occupancy modeling (D2, 5HT2A, H1, M1 receptors) • PANSS score prediction with time-dependent response kinetics (1-2 week onset, plateau by week 4) • Clinical efficacy thresholds based on D2 receptor occupancy (≥65%) • Placebo response component (15% baseline improvement) • Severity-adjusted response modeling Safety Assessment: • Dose-dependent toxicity risk calculation: agranulocytosis, seizures, cardiotoxicity • Reactive metabolite-glutathione depletion linkage • Cumulative toxicity scoring with time-dependent accumulation Key Physiological Parameters: • Adult baseline: 70 kg, 35 years, normal phenotypes across all genes • Bioavailability: 50% (accounting for first-pass metabolism) • Central volume: 50 L (scaled by body weight) • Clearance: 8.5 L/h with multi-pathway contributions • BBB permeability: 0.003 L/min/g with ABCB1-dependent efflux ratio of 3:1 • Therapeutic window: 350-600 ng/mL plasma concentration • Safety thresholds: Agranulocytosis (700 ng/mL), Seizures (1200 ng/mL), Cardiotoxicity (900 ng/mL)